ProCE Banner Activity


Planning Ahead: Development of a Seizure Action Plan With Rescue Medications


Watch this on-demand webcast of a live CCO presentation on epilepsy and the importance of incorporating rescue medications and seizure action plan into patient care.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit 

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 27, 2022

Expiration: October 26, 2023

No longer available for credit.



Jacqueline French

Jacqueline French, MD

Department of Epilepsy/Neurology
NYU Grossman School of Medicine
New York, New York

Marwan Noel Sabbagh

Marwan Noel Sabbagh, MD, FAAN, FANA

Moreno Family Chair for Alzheimer's Research
Vice Chairman for Research and Professor
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from

Neurelis Inc

Target Audience

This program is intended for healthcare professionals caring for patients with epilepsy, including neurologists, psychiatrists, nurse practitioners, physician associates/physician assistants, nurses, and pharmacists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Justify the need for a seizure action plan
  • Outline pharmacologic options for breakthrough seizures
  • Formulate strategies for counseling patients, family members, and caregivers on how to use rescue medications


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Jacqueline French, MD

Department of Epilepsy/Neurology
NYU Grossman School of Medicine
New York, New York

Jacqueline French, MD: consultant/advisor: Aeonian/Aeovian, Alterity, Anavex, Arvelle, Athenen/Carnot Pharma, Autifon, Baergic Bio, Biogen, Biohaven, BioMarin, BioXcel, Bloom Science, BridgeBio, Camp4, Cerebral Therapeutics, Cerevel, Coda, Corlieve, Crossject, Eisai, Eliem, Encoded Therapeutics, Engage Therapeutics, Engrail, Epalex, Epihunter, Epiminder, Epitel, Equilibre, Greenwich Biosciences, Grin Therapeutics, GW Pharma, Janssen, Jazz, Knopp Biosciences, Lipocine, LivaNova, Longboard, Lundbeck, Marinus, Mend Neuroscience, Merck, NeuCyte, Neumirna Therapeutics, Neurocrine, Neuroelectrics, Neuropace, NxGen Medicine, Ono, Otsuka, Ovid Therapeutics, Paladin, Passage Bio, Pfizer, Praxis, PureTech, Rafa, SK Life Sciences, Sofinnova, Stoke, Supernus, Synergia, Takeda, UCB , Ventus, Xenon, Xeris, Zogenix, Zynerba; researcher: the Epilepsy Study Consortium (funded by Eisai, Engage, Lundbeck, Pfizer, SK Life Science, Sunovion, UCB), the Epilepsy Study Consortium/Epilepsy Foundation (funded by UCB); other financial or material support: Arvelle, NeuCyte, Neurocrine, Praxis, Xenon.

Marwan Noel Sabbagh, MD, FAAN, FANA

Moreno Family Chair for Alzheimer's Research
Vice Chairman for Research and Professor
Department of Neurology
Barrow Neurological Institute
Phoenix, Arizona

Marwan Sabbagh, MD: consultant/advisor/speaker: Alzheon, Biogen, Eisai, Genentech-Roche, KeifeRx, Lilly, NeuroTherapia, Novo Nordisk, Signant Health, Synaptogenix, T3D; ownership interest (stocks/stock options): Athira, Cortexyme/Quince Therapeutics, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, Seq BioMarque, TransDermix, uMethod Health, Versanum; royalties or patent beneficiary: Humanix.

Staff Disclosure


Raquel Gaerlan,

Director, Scientific Services

Raquel Gaerlan has no relevant financial relationships to disclose.

Gabrielle Giacona,

Associate Scientific Director

Gabrielle Giacona: individual publicly traded stocks/stock options: AstraZeneca, Moderna, Teva.

Jessie Gibson, PHD, RN, AGPCNP-BC

Jessie Gibson, PhD, RN, AGPCNP-BC: advisor/consultant/speaker: Teva.

Amber Lemons, PharmD, BCPP

Director, Educational Strategy

Amber Lemons, PharmD, BCPP, has no relevant financial relationships to disclose.

Leslie Matson, MPA, PA-C

Leslie Matson, MPA, PA-C, has no relevant financial relationships to disclose.

Lisa Phipps, PharmD, PhD

Director, Science and Strategy, Neuroscience

Lisa Phipps, PharmD, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-267-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 23, 2023. PAs should only claim commensurate with the extent of their participation.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 27, 2022, through October 26, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.



The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with epilepsy who experience acute repetitive seizure episodes.